Worksite Cancer Screening Boosts Employee Morale

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 5
Volume 4
Issue 5

FORT LAUDERDALE, Fla-Worksite cancer screening programs are designed to help reduce cancer morbidity and mortality among employees, but have the added benefit of enhancing the employer's corporate image and boosting employee morale.

FORT LAUDERDALE, Fla-Worksite cancer screening programs are designedto help reduce cancer morbidity and mortality among employees,but have the added benefit of enhancing the employer's corporateimage and boosting employee morale.

"Cancer screening and education programs enhance a company'sreputation as a leader in employee health initiatives," saidRobert C. Black, president of Zeneca Pharmaceuticals, at the secondannual conference of the Industries' Coalition Against Cancer(ICAC).

Mr. Black noted that the worksite screening program at Zenecahas been applauded both within the company and within the communitywhere it operates, and receives frequent media attention, especiallythe breast cancer program, which has found eight cases of breastcancer in just 5 years.

Zeneca is viewed as a leader in helping large and small companiesand organizations develop and implement breast cancer screeningprograms, he said, due to its sponsorship of two Public BroadcastingSystem video conferences on worksite screening, as well as ICAC.

He said that the screening programs have helped improve employeemorale company wide. "Those who participate in our cancerscreening program have become its most effective promoters,"he said. "They truly become ambassadors for the company,both within its walls and within the local community."

Furthermore, when cancers are found, he said, Zeneca employeesrally around their coworkers with cancer by working extra hoursto give them time off, giving up vacation time to take over assignments,and providing a support system with hospital and home visits.In short, he said, "our employees do all the things thatmembers of a family, in this case a corporate family, do for eachother."

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content